ȸ¿ø°¡ÀÔ
Ȩ >  > 
¿ÀÄí¾Á 760mg,60Á¤(³ì³»Àå,Ȳ¹Ýº¯¼º)
È®´ëº¸±â
ÀÌÀü»óÇ° ¸ñ·Ï ´ÙÀ½»óÇ°
½ÃÁß°¡ : 168,000 ¿ø
ÆǸŰ¡ : 140,000¿ø
Àû¸³±Ý : 4,200 ¿ø
ÇÒÀÎÄíÆù :
¹è¼Ûºñ : [±âº»Á¤Ã¥]  4,900¿ø (100,000¿ø ÀÌ»ó ¹«·á¹è¼Û)
¼ö·® :
EA
Á¦Á¶»ç/¿ø»êÁö : Life Source Inc. / U.S.A
»óÇ°ÄÚµå : G0000001474
°í°´»óÇ°Æò : »óÇ°Æò0°³ »óÇ°Æò »óÇ°¹®ÀÇ
¹Ù·Î±¸¸Å Àå¹Ù±¸´Ï´ã±â °ü½É¸®½ºÆ®





¿ÀÅ¥-½Ç¢â

¿ÀÅ¥-½Ç(Ocu-Xyl¢â)Àº º¸Á¶ ÇÔÀ¯¼ººÐÀΠlutein °úzeaxanthin À¸·Î ´«ÀÇ °Ç°­À» °­È­ ½ÃÅ°¸ç ÁöÄÑÁÝ´Ï´Ù.


¹Ì±¹Æ¯Çã ´Ù¼¸ÆíÀ¸·Î ÁöÀû Àç»êÀÌ º¸È£ µÇ¾îÀִ ¿ÀÅ¥-½Ç(Ocu-Xyl¢â)ÀÌ ÇÔÀ¯ÇÏ°í ÀÖ´Â È¿´É¼ººÐµéÀº ¼¼°è ¼ö¸¹Àº °úÇÐÀڵ鿡 ÀÇÇØ ¿¬±¸µÇ¾î 500 ¿©Æí ÀÌ»óÀÇ ³í¹®µé¿¡ ÀÇÇØ ÀÔÁõµÇ¾îÀÖ½À´Ï´Ù.


³ì³»Àå°ú ³ëÀμº Ȳ¹Ýº¯¼ºµî ½Ã·ÂÀå¾Ö·Î °í½ÉÇϴºеéÀÇ ´«°Ç°­À» À§ÇÑÁ¦Ç°ÀÔ´Ï´Ù.


 

 

 

Glaucoma (³ì³»Àå)


¸ðµç»ç¶÷ÀÌ ³ªÀÌ°¡ µé¸é¼­ °¡Àå µÎ·Á¿ö Çϴ°ÍÁß Çϳª°¡ ½Ç¸íÇÏ´Â°Í ÀÔ´Ï´Ù.  °Ç°­ÇÑ ½Ã·ÂÀ» À¯ÁöÇϱâ À§Çؼ­´Â ¸Á¸·ÀÇ °Ç°­ÀÌ Áß¿äÇÕ´Ï´Ù. 


³ì³»Àå (Glaucoma)Àº »ç¶÷µé¿¡°Ô ½Ã·ÂÀå¾Ö´Â ¹°·Ð ½Ç¸íÇÏ°ÔÇÏ´Â °¡Àå Å« ÀÌÀ¯Áß ÇϳªÀÔ´Ï´Ù. ¹Ì±¹¿¡¼­´Â 200¸íÁß 1¸íÀÌ 50´ë ¹Ì¸¸¿¡ ³ì³»ÀåÀ¸·Î ½Ç¸íÇϸç 80´ë¿¡´Â 10¸íÁß 1¸íÀÌ ³ì³»ÀåÀ¸·Î ½Ç¸íÇÑ´Ù°í ÇÕ´Ï´Ù.


³ì³»Àå¿¡´Â ±Þ¼º ³ì³»Àå°ú ¸¸¼º ³ì³»ÀåÀÌ ÀÖ½À´Ï´Ù. ÇöÀç ¹Ì±¹ÀÇ ³ì³»Àå ȯÀÚµéÁß 90%Á¤µµ°¡ ¸¸¼º ³ì³»ÀåÀ» ¾Î°íÀÖÀ¸¸ç ³ª¸ÓÁö 10%´Â ±Þ¼º ³ì³»ÀåÀ¸·Î ½Ã·Â¿¡ ¼Õ»óÀ» ÀÔ°í ÀÖ½À´Ï´Ù.  µ¿¾çÀεéÀº ¼­¾çÀÎ µéº¸´Ù ´õ¸¹Àº »ç¶÷µéÀÌ (´ë·«~50%) ±Þ¼º ³ì³»ÀåÀ¸·Î ½Ã·Â ¼Õ»óÀ» ÀÔ°í ½Ç¸íÇÏ°í ÀÖ½À´Ï´Ù. 


ÃÖ±Ù °úÇÐÀÚµéÀº Ä¡¸ÅÀÇ ¿øÀÎÀÎ µ¶¼º ´Ü¹éÁú º£Å¸ ¾Æ¹Ð·ÎÀ̵å beta-amyloid(A¥â) ¸¦ ³ì³»Àå ȯÀÚµéÀÇ ¸Á¸·¿¡¼­ ¹ß°ßÇßÀ¸¸ç, ¹Ù·Î À̵¶¼º ´Ü¹éÁúÀÌ ¸Á¸·ÀÇ ½Ã½Å°æ ¼¼Æ÷µéÀ» ¼Õ»óÀÔÇô »ç¸ê½ÃÅ´À¸·Î ³ì³»ÀåÀ¸·Î ÁøÀü ÇÏ°ÔÇÏ´Â ¿øÀÎÁß Çϳª ¶ó´Â°ÍÀ» ¹àÇô ³»¾ú½À´Ï´Ù.  µû¶ó¼­ ³ì³»ÀåÀº ´«¿¡ ¿À´Â Ä¡¸Å¶ó°í ¸»ÇÒ¼ö ÀÖ½À´Ï´Ù..


¿ÀÅ¥-½Ç (Ocu-Xyl¢â) ÀÌ ÇÏ´ÂÀÛ¿ë? 


ÀúÈñ ¿ÀÅ¥-½ÇÀÌ º¸À¯ÇÏ°í ÀÖ´Â ÀÔÁõµÈ °úÇаú È¿´É ¼ººÐµéÀÌ ¹Ù·Î ÀÌ µ¶¼º ´Ü¹éÁúÀ» Á¦°ÅÇÏ°í ¸Á¸·ÀÇ ½Ã½Å°æ ¼¼Æ÷¸¦ º¸È£ÇÔÀ¸·Î ³ì³»Àå°ú ³ëÀμº Ȳ¹Ýº¯¼ºÀ» ¿¹¹æÇÏ°í Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÒ¼öÀÖ´Ù´Â »ç½ÇÀ» ¿©·¯ÆíÀÇ Æ¯Çãµé°ú ¼ö¸¹Àº ³í¹®µé·Î Áõ¸í µÇ¾î ÀÌÁ¦ ¸ðµç »ç¶÷µé¿¡°Ô µµ¿òÀÌ µÉ¼öÀÖ°Ô µÇ¾ú½À´Ï´Ù.


³ì³»Àå°ú ³ëÀμº Ȳ¹Ýº¯¼ºÀ» ÀÏÀ¸Å°´Â ¿øÀÎÁßÇϳªÀÎ µ¶¼º ´Ü¹éÁú º£Å¸ ¾Æ¹Ð·ÎÀ̵带 ¿ÀÅ¥-½ÇÀº: 

(1) ¸Á¸· (retina) ¿¡ ½×¿©ÀÖ´Â µ¶¼º ´Ü¹éÁú º£Å¸ ¾Æ¹Ð·ÎÀ̵堸¦ ³ì¿© ¹ö¸²À¸·Î ½Ã½Å°æ ¼¼Æ÷¸¦ º¸      È£ÇÑ´Ù, 

(2) ¸Á¸·¿¡ µ¶¼º ´Ü¹éÁú º£Å¸ ¾Æ¹Ð·ÎÀ̵堰¡ ½×ÀÌ´Â °ÍÀ» ¹æÁöÇÑ´Ù, 

(3) ½Ã½Å°æ ¼¼Æ÷¸¦ º£Å¸ ¾Æ¹Ð·ÎÀ̵å ÀÇ µ¶¼º¿¡¼­ ºÎÅÍ º¸È£ÇÑ´Ù, 

(4) ¼Õ»óÀÔÀº ½Ã½Å°æ ¼¼Æ÷¸¦ ȸº¹ ½ÃŲ´Ù. 

(5) ½Ã½Å°æ ¼¼Æ÷¸¦ È°¼ºÈ­ ½ÃÅ´À¸·Î ´«ÀÇ °Ç°­À» À¯Áö ½ÃÄÑÁØ´Ù.


Age-related Macular Degeneration (AMD) 

(³ëÀμº Ȳ¹Ýº¯¼º)


³ëÀμº Ȳ¹Ýº¯¼ºÀº °í·ÉÈ­ µÇ¾î °¡´Â Çö´ë »çȸ¿¡¼­ 50´ë ÀÌ»óÀÇ °í·ÉÀڵ鿡°Ô ³ì³»Àå°ú  ´õºÒ¾î ½Ã·ÂÀå¾Ö¿Í ½Ç¸íÀ» ÀÏÀ¸Å°´Â ¿øÀÎÁß ÇϳªÀÔ´Ï´Ù. ¼­¾ç¿¡¼­´Â 65¼¼ÀÌ»ó ³ë³âÃþ ½Ç¸í ¿øÀÎ 1À§°¡ ³ëÀμº Ȳ¹Ýº¯¼ºÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. 


¸Á¸·Àº ¾È±¸ÀÇ ¾ÈÂʸéÀ» µ¤´Â ¾ãÀº¸· À¸·Î ºûÀ» ¹Þ¾Æ ½Ã½Å°æÀ» ÅëÇÏ¿© ³ú·Î ÀÚ±ØÀ» º¸³»´Â ½Å°æÁ¶Á÷À¸·Î Ä«¸Þ¶óÀÇ Çʸ§°ú °°Àº ¿ªÇÒÀ» ÇÕ´Ï´Ù.  ¸Á¸·ÀÇ Á᫐ ºÎºÐÀ» Ȳ¹Ý À̶ó°íÇÏ¸ç ¿©±â¿¡ ÀϾ´Â ÅðÇ༺ º´¼ºÀ» Ȳ¹Ýº¯¼ºÀ̶ó°í ÇÕ´Ï´Ù. 


¸Á¸·Á¶Á÷Àº ³ªÀÌ°¡ µé¾î°¨¿¡ µû¶ó ¾ã¾ÆÁö°í ¼Õ»ó ¹Þ°ÔµÇ¸ç ³ëÆó¹°ÀÌ ÃàÀûµÇ¾î µå·ç¼¾(Drusen)À̶ó´Â º¯È­°¡ ³ªÅ¸³³´Ï´Ù.  ÀÌ·¯ÇÑ º¯È­·Î ÀÎÇØ È²¹ÝºÎ´Â ±â´ÉÀ» Á¡Â÷ ¼Ò½ÇÇÏ°Ô µË´Ï´Ù.  ¿¬·É°ü·Ã Ȳ¹Ýº¯¼ºÀº 2°¡Áö ÇüÅ·Π³ª´­¼ö ÀÖ½À´Ï´Ù. ´Ü´ÜÇÏ°Ô º¸ÀÌ´Â °æ¼º µå·ç¼¾°ú ¸Á¸· À§ÃàÀ» º¸À̸ç ÁøÇàÀÌ ´À¸° ºñ»ïÃ⼺(°Ç¼ºÈ²¹Ýº¯¼º)ÀÌ90%¸¦ Â÷ÁöÇÏ¸ç ¹«¸£°Ô º¸ÀÌ´Â ¿¬¼º µå·çÁ¨°ú ¼¶À¯Ç÷°ü¸·ÀÇ Áõ½ÄÀ» º¸À̸ç ÁøÇàÀÌ ±Þ°ÝÇÑ »ïÃ⼺(½À¼ºÈ²¹Ýº¯¼º)ÀÌ 10%¸¦ Â÷ÁöÇÕ´Ï´Ù. 


°Ç¼º Ȳ¹Ýº¯¼ºÀÌ ¾ÇÈ­µÇ¾î ¸Á¸· ÇϺο¡ Çü¼ºµÈ ÀÛÀº Ç÷°ü¸·À¸·Î ºÎÅÍ Ç÷¾× ¼ººÐÀÌ ´©ÃâµÇ¾î ¸Á¸·ÃâÇ÷°ú Ȳ¹ÝºÎÁ¾À» ÀÏÀ¸Å°¸ç ½À¼º Ȳ¹Ýº¯¼ºÀ¸·Î ¾ÇÈ­ µÉ¼öÀÖÀ¸¸ç ÀÌ·¯ÇÑ Ç÷°ü¸·ÀÌ Áõ½ÄÇÏ°Ô µÇ¸é Ȳ¹ÝºÎ¿¡ ÃâÇ÷À̳ª ¹ÝÈç(ÈäÅÍ)À» ³²±æ¼ö ÀÖ½À´Ï´Ù.  À̶§ Ȳ¹ÝÀÇ Æı«°¡ ½ÉÇÑ°æ¿ì ªÀº ½Ã°£³»¿¡ ½Ç¸íÇÏ°Ô µË´Ï´Ù.


ÇöÀç 66¼¼ ¿¡¼­ 74¼¼ »çÀÌÀÇ Àα¸ 10% Á¤µµ°¡ Ȳ¹Ýº¯¼ºÀ» ¾Î°íÀÖÀ¸¸ç, 75¼¼ ¿¡¼­ 85¼¼ »çÀÌÀÇ Àα¸30%°¡ Ȳ¹Ýº¯¼ºÀ» ¾Î°í ÀÖ½À´Ï´Ù.  ÇöÀç ¹Ì±¹ ¿¡¼­´Â õ¸¸¸í °¡·®ÀÌ ÀÌ Áúº´À» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù.


ÃÖ±Ù °úÇÐÀÚµéÀº Ä¡¸ÅÀÇ ¿øÀÎÀÎ µ¶¼º ´Ü¹éÁú º£Å¸ ¾Æ¹Ð·ÎÀ̵带 Ȳ¹ÝÀÇ µå·ç¼¾¿¡¼­ ¹ß°ßÇßÀ¸¸ç, ¹Ù·Î ÀÌ µ¶¼º ´Ü¹éÁúÀÌ È²¹ÝÀÇ ½Ã½Å°æ ¼¼Æ÷µéÀ» ¼Õ»óÀÔÇô »ç¸ê ½ÃÅ´À¸·Î ½Ç¸íÇÏ°Ô ÇÏ´Â ¿øÀÎ Áß Çϳª ¶ó´Â°ÍÀ» ¹àÇô ³»¾ú½À´Ï´Ù.  µû¶ó¼­ ³ëÀμº Ȳ¹Ýº¯¼ºÀº ³ì³»Àå°ú ´õºÒ¾î ´«¿¡ ¿À´Â Ä¡¸Å¶ó°í ÀÎÁ¤ÇÏ°í ÀÖ½À´Ï´Ù.



º¹¿ë¹ý


ÇÏ·ç¿¡ 1-2Á¤À» ¹°°ú ÇÔ²² ¼·Ãë





Ocu-Xyl ¢â

Both Glaucoma and AMD that leads to blindness and visual impairments are considered Alzheimer¡¯s disease of the eye.


The biological efficacy of patents protected natural constituents in Ocu-Xyl¢â has been confirmed by over 500 scientific publications from scientists all over the world.


Promotes Eye Health against Glaucoma and Age-related Macular Degeneration.


 

 

 

Glaucoma 


In order to maintain good eye health, supporting healthy retinal function becomes utmost importance because good vision is critical to everyday function. 


Glaucoma is one of the leading causes of blindness and visual impairment, affecting 1 in 200 people aged fifty and younger, and 1 in ten over the age of eighty. There are two main types of glaucoma: open-angle glaucoma and closed-angle glaucoma. Open-angle glaucoma accounts for90% of glaucoma cases in the United States while closed-angle glaucoma accounts for less than 10%. In other nations, particularly Asian countries, the close-angle glaucoma accounts for as many as half of glaucoma cases. 


Scientists have recently found beta-amyloid (A¥â) in the retina of glaucoma patients where A¥âdeposits cause retinal ganglion cell death, suggesting that if we can eliminate the accumulation of A¥â in the retina, we may be able to prevent the onset of glaucoma


How Does Ocu-Xyl¢â Work? 


As we now know A¥â as one of the causes of the onset of glaucoma and AMD, the onset of glaucoma and AMD may be resolved by:


(1) removing the aggregated A¥â in the retina, 

(2) preventing the accumulation of A¥â in the retina, 

(3) protecting retinal cells from A¥â toxicity, 

(4) repairing the damaged retinal cells, and 

(5) increasing retinal cell viability.


Age-related Macular Degeneration (AMD)


AMD is another disease in the eye that causes blindness and visual impairments in older adults (>50 years). AMD is characterized by the formation of drusen, extracellular deposits associated with atrophy of the retinal pigmented epithelium (RPE) that cause disturbance in the trans-epithelial barrier to result in photoreceptor death in the macula between the retinal pigment epithelium and the underlying choroid. Approximately 10% of population between 66 to 74 years of age show signs of macular degeneration, that increases to 30% of population 75 to 85 years of age.


AMD occurs in ¡°dry¡± and ¡°wet¡± forms. In the dry form of AMD, drusen accumulates between the retina and the choroid to cause atrophy to the retinal pigment epithelial layer below the retina to cause vision loss through loss of photoreceptors (rods and cones) in the macula of the eye. 


In the wet form of AMD, which is more severe but only accounts for about 10% of the AMD patients, blood vessels grow from the choroid behind the retina to cause detachment of retina to result in acute vision loss. In the drusen of AMD, an excess extracellular A¥â deposits, that is one of the leading causes of AD and glaucoma, was found along with characteristic degeneration of photoreceptors in the retina. This finding suggests that if we can eliminate the accumulation of A¥â in the drusen, we may be able to prevent the onset of AMD.





Ocu-Xyl¢â of Core LifeSource Inc. is 100% natural.

  • 80,000¿ø ÀÌ»ó ±¸¸ÅÇÏ½Ã¸é ¹«·á¹è¼ÛÀÔ´Ï´Ù.
  • ±¸¸Å±Ý¾×ÀÌ 80,000¿ø ÀÌÇÏÀÏ °æ¿ì ¹è¼Û·á(4,500¿ø )¸¦ ºÎ´ãÇÏ¼Å¾ß ÇÕ´Ï´Ù.
  • ±¸¸ÅÀÚ »çÁ¤À¸·Î ±³È¯À̳ª ȯºÒÀ» ÇÒ °æ¿ì ¿Õº¹ ¹è¼Û·á´Â ±¸¸ÅÀÚ ºÎ´ãÀ̸ç, »óÇ°¿¡ ÀÌ»óÀÌ Àְųª À߸ø ¹è¼ÛÀÌ µÈ °æ¿ì¿¡´Â ¿Õº¹ ¹è¼Û·á¸¦ À£ºùij³ª´Ù°¡ ºÎ´ãÇÕ´Ï´Ù.
  • µµ¼­Áö¿ª(Á¦ÁÖµî)À» Á¦¿ÜÇÏ°í´Â Àü±¹ ¾î´À°÷À̳ª ¹è¼Û·á°¡ °°½À´Ï´Ù.
  • ¹è¼ÛÀº °áÁ¦È®ÀÎÈÄ 4ÀÏ~6ÀÏ(¿µ¾÷ÀÏ) À̸ç,¹è¼ÛÁ¶È¸¿¡¼­ ¹è¼ÛÇöȲÀ» È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
  • °øÈÞÀÏ, ±âŸ ÈÞ¹«ÀÏ¿¡´Â ¹è¼ÛµÇÁö ¾ÊÀ¸¸ç, ¿Â¶óÀÎ ¼Û±ÝÀ» ÇϽŠ°æ¿ì¿¡´Â ÀÔ±ÝÈ®ÀÎ ´çÀϺÎÅÍ ¹è¼Û±â°£¿¡ Æ÷ÇÔÇÕ´Ï´Ù.
  • ÁÖ¹®¼­ ÀÛ¼º½Ã Áֹεî·Ï¹øÈ£ ¿ä±¸´Â ij³ª´Ù¿¡¼­ Çѱ¹À¸·Î Åë°üÇÒ¶§ Çѱ¹¼¼°ü¿¡¼­ ¿ä±¸Çϴ°ÍÀ¸·Î½á Áֹεî·Ï¹øÈ£°¡ ¾øÀ¸¸é Åë°ü ÀÚü°¡ ¾ÈµÇ´Ï ÀÌÁ¡ À¯ÀÇÇϽñ⠠¹Ù¶ø´Ï´Ù.

±³È¯ ¹× ¹ÝÇ°ÀÌ ºÒ°¡´ÉÇÑ °æ¿ì 

  • °í°´´ÔÀÇ Ã¥ÀÓÀÖ´Â »çÀ¯·Î »óÇ°µîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì.
  • °í°´´ÔÀÇ »ç¿ë ¶Ç´Â ÀϺΠ¼Òºñ¿¡ ÀÇÇÏ¿© »óÇ°µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
  • ½Ã°£ÀÌ °æ°úµÇ¾î ÀçÆǸŰ¡ °ï¶õÇÒ Á¤µµ·Î »óÇ°µîÀÇ °¡Ä¡°¡ »ó½ÇµÈ °æ¿ì

    ¡Ø °í°´º¯½É¿¡ ÀÇÇÑ ±³È¯, ¹ÝÇ°ÀÎ °æ¿ì »óÇ° ¹Ý¼Û¿¡ µå´Â ºñ¿ëÀº °í°´´Ô²²¼­ ºÎ´ãÇÏ¼Å¾ß ÇÕ´Ï´Ù.

 

1 ±¸¸ÅÈ®Á¤ ¡Ú¡Ú¡Ú¡Ú yk*** 2018/11/08
ÀÌÀü±ÛÀÌ Á¸ÀçÇÏÁö ¾Ê½À´Ï´Ù.1´ÙÀ½±ÛÀÌ Á¸ÀçÇÏÁö ¾Ê½À´Ï´Ù.
µî·ÏµÈ ±ÛÀÌ ¾ø½À´Ï´Ù.
À£ºùij³ª´Ù ¾ËƼÁö ¿À¸Þ°¡3 ·Î¾âÁ¦¸® ÇÁ·Î¹ÙÀÌ¿Àƽ½º À¯»ê±Õ Äݶó°Õ ³ë´Ï ±×·Î½ºÅÛÆ÷ Á¾ÇÕ ºñŸ¹Î ŸƮü¸® Æú¸®ÄÚ»ç³î ÇÁ·ÎÆú¸®½º
(1°³)

ȨÀ¸·Î | È¸»ç¼Ò°³ | ÀÌ¿ë¾È³» | ÀÌ¿ë¾à°ü | °í°´¼¾ÅÍ | ¾ÆÀ̵ð/ºñ¹Ð¹øȣã±â
7171 yonge st. thornhill | ȸ»ç¸í : À£ºùij³ª´Ù | ´ëÇ¥ÀÚ¸í : Yong Choi
»ç¾÷ÀÚµî·Ï¹øÈ£ : 221131154 | Åë½ÅÆǸž÷½Å°í Á¦4654633È£ I °³ÀÎÁ¤º¸ º¸È£ °ü¸®ÀÚ : JasminChoi
¹®ÀÇ ÀüÈ­ : 070-5103-1897 I Fax 025643210
Copyright ¨Ï2024 Wellbeing Canada All rights reserved.